Shenzhen Binder Biotechnology

Shenzhen Binder Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shenzhen, China, specializing in the development of innovative immune cell therapies. The company focuses on next-generation CAR-T and TCR-T technologies to treat both hematological malignancies and refractory solid tumors. Its proprietary Binder-T platform enables the design of armored and universal cell products intended to overcome the immunosuppressive tumor microenvironment. Binder Biotechnology's pipeline includes candidates targeting CD19, BCMA, and GPC3, with several programs currently undergoing clinical evaluation. The company has established GMP-compliant manufacturing facilities to support its internal R&D and clinical trial requirements. By leveraging its expertise in synthetic biology and immunology, the company aims to provide more effective and accessible precision medicine solutions for cancer patients globally.